BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25000999)

  • 1. Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Prieto JC; Bajo AM
    Invest New Drugs; 2014 Oct; 32(5):871-82. PubMed ID: 25000999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
    Guo J; Schally AV; Zarandi M; Varga J; Leung PC
    Reprod Biol Endocrinol; 2010 May; 8():54. PubMed ID: 20509930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers.
    Perez R; Schally AV; Vidaurre I; Rincon R; Block NL; Rick FG
    Oncotarget; 2012 Sep; 3(9):988-97. PubMed ID: 22941871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.
    Muñoz-Moreno L; Arenas MI; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Oncotarget; 2016 Aug; 7(32):52195-52206. PubMed ID: 27448980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
    Busto R; Schally AV; Varga JL; Garcia-Fernandez MO; Groot K; Armatis P; Szepeshazi K
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11866-71. PubMed ID: 12186980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.
    Rick FG; Schally AV; Szalontay L; Block NL; Szepeshazi K; Nadji M; Zarandi M; Hohla F; Buchholz S; Seitz S
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1655-60. PubMed ID: 22307626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
    Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
    Barabutis N; Schally AV
    Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20470-5. PubMed ID: 19075233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
    Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.
    Muñoz-Moreno L; Bajo AM; Prieto JC; Carmena MJ
    Mol Cell Endocrinol; 2017 May; 446():59-69. PubMed ID: 28193499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
    Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
    Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.